Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has announced that Dorothy Bray, Ph.D., representing ImmunoClin Ltd, has joined the ReceptoPharm Scientific Advisory Board. Dr. Bray served as the Director of HIV Clinical Development at GlaxoSmithKline (GSK) with global responsibility for their clinical trials program. GSK is currently the largest provider of HIV antiretroviral drugs with an estimated 40% global market share.
"I am pleased to join the ReceptoPharm Scientific Advisory Board," explained Dr. Bray. "I look forward to contributing directly to ReceptoPharm's current and future clinical trial programs and developing focused strategies to bring their drugs to market," she added.
Dr. Bray has significant expertise in clinical development and market positioning for novel drugs. Her key skills include broad scientific and regulatory knowledge, strategic planning, and commercial awareness.
"Dr. Bray and her associates at ImmunoClin Ltd will add tremendous value to ReceptoPharm and Nutra Pharma," commented Dr. Paul Reid, CEO of ReceptoPharm. "We welcome her to the Scientific Advisory Board and we look forward to a close working relationship with her," he added.
ReceptoPharm is currently studying RPI-MN as a treatment for HIV and RPI-78M as a treatment for Multiple Sclerosis (MS), and Adrenomyeloneuropathy (AMN). They recently announced their approval by the British Medicines and Healthcare Regulatory Agency to begin Phase II human trials for the treatment of AMN.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The addition of the former Global Clinical Development Director at GlaxoSmitheKline to the ReceptoPharm Scientific Advisory Board should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.